Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free DFTX Stock Alerts

Definium Therapeutics (DFTX) Financials

Definium Therapeutics logo
$44.29 +0.19 (+0.43%)
As of 07/17/2026 04:00 PM Eastern
Compare
Annual Income Statements for Definium Therapeutics

Annual Income Statements for Definium Therapeutics

This table shows Definium Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -34 -93 -57 -96 -109 -184
Consolidated Net Income / (Loss)		 -34 -93 -57 -96 -109 -184
Net Income / (Loss) Continuing Operations		 -34 -93 -57 -96 -109 -184
Total Pre-Tax Income 		-34 -94 -57 -96 -109 -184
Total Operating Income		 -33 -94 -66 -94 -104 -166
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 33 94 66 94 104 166
Selling, General & Admin Expense		 14 59 30 42 39 49
Research & Development Expense		 19 35 36 52 65 118
Total Other Income / (Expense), net		 -0.91 -0.34 9.54 -1.87 -4.76 -17
Interest Expense		 0.16 0.36 -1.50 0.92 -0.26 5.48
Interest & Investment Income		 - - - 5.58 12 11
Other Income / (Expense), net		 -0.74 0.02 8.04 -6.53 -17 -23
Basic Earnings per Share		 ($0.13) ($3.40) ($1.84) ($2.44) ($1.54) ($2.06)
Weighted Average Basic Shares Outstanding		 266.22M 27.38M 30.86M 39.16M 70.46M 89.33M
Diluted Earnings per Share		 ($0.13) ($3.40) ($1.84) ($2.44) ($1.54) ($2.06)
Weighted Average Diluted Shares Outstanding		 266.22M 27.38M 30.86M 39.16M 70.46M 89.33M
Weighted Average Basic & Diluted Shares Outstanding		 266.22M 410.66M 38.06M 41.33M 75.37M 99.70M

Quarterly Income Statements for Definium Therapeutics

This table shows Definium Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -18 -24 -54 -5.85 -14 -35 -23 -43 -67 -50 -77
Consolidated Net Income / (Loss)		 -18 -24 -54 -5.85 -14 -35 -23 -43 -67 -50 -77
Net Income / (Loss) Continuing Operations		 -18 -24 -54 -5.85 -14 -35 -23 -43 -67 -50 -77
Total Pre-Tax Income 		-18 -24 -54 -5.85 -14 -35 -23 -43 -67 -50 -77
Total Operating Income		 -22 -22 -22 -24 -25 -32 -32 -41 -46 -48 -59
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 22 22 22 24 25 32 32 41 46 48 59
Selling, General & Admin Expense		 8.41 11 10 9.81 7.60 11 8.80 11 15 14 18
Research & Development Expense		 13 12 12 15 17 22 23 30 31 34 41
Total Other Income / (Expense), net		 3.69 -1.66 -32 19 11 -2.28 8.81 -1.84 -22 -2.86 -18
Interest Expense		 0.33 0.44 0.43 -2.08 0.73 0.66 0.60 2.34 1.27 1.27 1.25
Interest & Investment Income		 1.49 1.35 1.66 3.12 3.51 3.28 2.43 2.77 2.26 3.49 3.46
Other Income / (Expense), net		 2.53 -2.57 -33 13 8.33 -4.90 6.98 -2.28 -23 -5.08 -20
Basic Earnings per Share		 ($0.45) ($0.61) ($1.14) ($0.08) ($0.18) ($0.14) ($0.27) ($0.50) ($0.78) ($0.51) ($0.71)
Weighted Average Basic Shares Outstanding		 39.72M 39.16M 47.86M 71.91M 77.91M 70.46M 85.07M 85.35M 85.89M 89.33M 108.79M
Diluted Earnings per Share		 ($0.45) ($0.61) ($1.14) ($0.26) ($0.27) $0.13 ($0.35) ($0.50) ($0.78) ($0.43) ($0.71)
Weighted Average Diluted Shares Outstanding		 39.72M 39.16M 47.86M 75.30M 80.24M 70.46M 87.09M 85.35M 85.89M 89.33M 108.79M
Weighted Average Basic & Diluted Shares Outstanding		 40.09M 41.33M 71.87M 72.14M 73.33M 75.37M 75.55M 76.09M 98.51M 99.70M 109.07M

Annual Cash Flow Statements for Definium Therapeutics

This table details how cash moves in and out of Definium Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 73 53 8.60 -42 174 -16
Net Cash From Operating Activities		 -24 -46 -50 -64 -79 -132
Net Cash From Continuing Operating Activities		 -24 -46 -50 -65 -79 -132
Net Income / (Loss) Continuing Operations		 -34 -93 -57 -96 -109 -184
Consolidated Net Income / (Loss)		 -34 -93 -57 -96 -109 -184
Amortization Expense		 0.00 2.62 3.18 3.26 0.53 -1.82
Non-Cash Adjustments To Reconcile Net Income		 11 42 7.26 22 32 45
Changes in Operating Assets and Liabilities, net		 -0.58 2.59 -3.78 6.28 -3.34 9.44
Net Cash From Investing Activities		 0.00 -0.30 0.00 0.00 0.00 -152
Net Cash From Continuing Investing Activities		 0.00 -0.30 0.00 0.00 0.00 -152
Purchase of Investments		 - - - - 0.00 -268
Sale and/or Maturity of Investments		 - - - - 0.00 117
Net Cash From Financing Activities		 97 99 59 22 253 267
Net Cash From Continuing Financing Activities		 97 99 59 22 253 267
Repayment of Debt		 - - 0.00 -0.84 -0.13 -22
Repurchase of Common Equity		 -0.40 - - 0.00 -16 -16
Issuance of Debt		 - - 0.00 15 10 42
Issuance of Common Equity		 72 82 60 7.53 251 259
Other Financing Activities, net		 25 17 -0.99 0.16 8.43 4.39
Effect of Exchange Rate Changes		 0.28 0.74 -0.31 0.08 -0.03 -0.01
Cash Interest Paid		 - - 0.00 0.53 2.22 5.34

Quarterly Cash Flow Statements for Definium Therapeutics

This table details how cash moves in and out of Definium Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.80 -18 153 -9.20 52 -22 -191 -49 -13 238 4.68
Net Cash From Operating Activities		 -17 -21 -17 -20 -17 -25 -29 -30 -30 -43 -43
Net Cash From Continuing Operating Activities		 -17 -21 -17 -20 -17 -25 -29 -30 -30 -43 -43
Net Income / (Loss) Continuing Operations		 -18 -24 -54 -5.85 -14 -35 -23 -43 -67 -50 -77
Consolidated Net Income / (Loss)		 -18 -24 -54 -5.85 -14 -35 -23 -43 -67 -50 -77
Amortization Expense		 0.79 0.89 0.53 - - 0.73 0.00 -2.42 0.14 0.46 0.59
Non-Cash Adjustments To Reconcile Net Income		 1.64 5.90 38 -11 -4.52 8.89 -3.61 7.48 29 11 28
Changes in Operating Assets and Liabilities, net		 -1.14 -3.80 -0.68 -3.45 1.01 -0.23 -2.46 8.08 8.10 -4.29 5.45
Net Cash From Investing Activities		 - - 0.00 - - - -162 -40 15 35 42
Net Cash From Continuing Investing Activities		 - - 0.00 - - - -162 -40 15 35 42
Purchase of Investments		 - - 0.00 - - - -162 -73 -27 -6.02 0.00
Sale and/or Maturity of Investments		 - - - - - - 0.00 - 42 41 42
Net Cash From Financing Activities		 17 2.59 169 11 69 3.81 1.00 20 0.75 246 5.31
Net Cash From Continuing Financing Activities		 17 2.59 169 11 69 3.81 1.00 20 0.75 246 5.31
Repayment of Debt		 -0.80 -0.04 -0.13 - - - 0.00 -22 - - 0.00
Repurchase of Common Equity		 - - -8.72 - - - 0.00 - - -16 0.00
Issuance of Debt		 15 - - - - - 0.00 - - - 0.00
Issuance of Common Equity		 3.09 2.59 0.00 -2.09 -0.25 - 0.19 - 0.23 259 0.28
Other Financing Activities, net		 0.11 0.05 178 2.88 70 3.81 0.82 0.10 0.52 2.96 5.03
Effect of Exchange Rate Changes		 0.03 -0.03 - 0.00 -0.01 0.00 -0.01 0.03 -0.02 0.00 0.00
Cash Interest Paid		 0.10 0.43 0.43 0.44 0.67 0.68 0.60 2.59 1.46 0.69 1.05

Annual Balance Sheets for Definium Therapeutics

This table presents Definium Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 82 164 170 125 302 440
Total Current Assets		 82 137 146 104 282 419
Cash & Equivalents		 80 134 142 100 274 258
Short-Term Investments		 - - - - 0.00 154
Prepaid Expenses		 1.43 3.68 3.91 4.17 7.88 7.73
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 27 24 21 21 21
Long-Term Investments		 - - - - - 0.00
Goodwill		 0.00 20 20 20 20 20
Other Noncurrent Operating Assets		 - 0.00 0.33 0.22 0.61 0.86
Total Liabilities & Shareholders' Equity		 82 164 170 125 302 440
Total Liabilities		 5.65 12 19 46 61 108
Total Current Liabilities		 3.01 10 18 32 39 67
Accounts Payable		 2.02 4.18 2.11 4.14 2.01 5.35
Accrued Expenses		 0.99 6.23 5.88 12 13 20
Other Current Liabilities		 - 0.00 9.90 16 24 41
Total Noncurrent Liabilities		 2.64 1.93 1.18 14 22 41
Long-Term Debt		 - - 0.00 14 22 41
Other Noncurrent Operating Liabilities		 2.64 1.93 1.18 0.03 0.00 0.50
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 76 152 151 78 241 332
Total Preferred & Common Equity		 76 152 151 78 241 332
Total Common Equity		 76 152 151 78 241 332
Common Stock		 120 288 345 368 640 914
Retained Earnings		 -45 -138 -194 -290 -399 -583
Accumulated Other Comprehensive Income / (Loss)		 0.28 1.05 0.63 0.34 0.82 1.09

Quarterly Balance Sheets for Definium Therapeutics

This table presents Definium Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 181 156 142 142 276 268 320 275 265 237 401
Total Current Assets		 157 132 120 120 255 248 299 222 189 216 381
Cash & Equivalents		 155 129 117 118 252 243 295 83 33 20 263
Short-Term Investments		 - - - - - - - 130 150 189 111
Prepaid Expenses		 1.83 3.00 2.90 2.39 3.14 4.56 4.07 9.26 6.14 6.78 7.14
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 24 23 22 21 20 20 20 54 76 21 21
Long-Term Investments		 - - - - - - - 33 55 0.00 0.00
Goodwill		 20 20 20 20 20 20 20 20 20 20 20
Other Noncurrent Operating Assets		 - 0.30 0.27 0.23 0.14 0.53 0.49 0.61 1.17 1.15 0.81
Total Liabilities & Shareholders' Equity		 181 156 142 142 276 268 320 275 265 237 401
Total Liabilities		 27 25 36 46 79 66 58 53 80 106 122
Total Current Liabilities		 26 24 35 31 65 42 33 30 38 65 81
Accounts Payable		 0.82 2.32 8.58 7.69 7.60 2.94 2.15 2.27 4.22 8.11 7.13
Accrued Expenses		 7.47 6.69 9.95 9.96 9.97 8.23 8.80 11 15 19 25
Other Current Liabilities		 18 15 17 14 48 31 22 17 19 38 49
Total Noncurrent Liabilities		 1.28 1.09 0.99 14 14 24 24 22 42 41 41
Long-Term Debt		 - - - 14 14 24 24 22 41 40 41
Other Noncurrent Operating Liabilities		 1.28 1.09 0.99 0.35 0.02 0.00 0.00 - 0.54 0.52 0.56
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 154 130 106 96 196 202 262 223 185 131 279
Total Preferred & Common Equity		 154 130 106 96 196 202 262 223 185 131 279
Total Common Equity		 154 130 106 96 196 202 262 223 185 131 279
Common Stock		 342 349 354 362 540 552 626 644 650 662 938
Retained Earnings		 -190 -219 -248 -266 -345 -350 -364 -422 -465 -532 -660
Accumulated Other Comprehensive Income / (Loss)		 0.74 0.64 0.36 0.78 0.84 0.83 0.82 0.80 0.81 1.00 0.82

Annual Metrics And Ratios for Definium Therapeutics

This table displays calculated financial ratios and metrics derived from Definium Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -170.09% 39.58% -76.25% -22.76% -59.29%
EBIT Growth		 0.00% -177.84% 37.88% -72.23% -20.02% -57.08%
NOPAT Growth		 0.00% -184.15% 29.33% -41.51% -10.71% -60.04%
Net Income Growth		 0.00% -174.14% 38.95% -68.55% -13.52% -69.12%
EPS Growth		 0.00% -174.14% 45.88% -32.61% 36.89% -33.77%
Operating Cash Flow Growth		 0.00% -94.19% -9.42% -28.37% -22.94% -66.26%
Free Cash Flow Firm Growth		 0.00% 0.00% 57.89% -33.46% -40.92% -26.42%
Invested Capital Growth		 0.00% 528.89% -51.59% -184.80% -40.29% -270.60%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 17.72% -23.82% -11.88% -8.87%
EBIT Q/Q Growth		 0.00% 0.00% 16.91% -23.02% -11.67% -8.79%
NOPAT Q/Q Growth		 0.00% 0.00% 5.23% -9.71% -10.95% -10.00%
Net Income Q/Q Growth		 0.00% 0.00% 17.35% -24.70% -11.12% -9.34%
EPS Q/Q Growth		 0.00% 0.00% 21.70% -26.42% -22.22% -37.33%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -11.12% -13.62% -6.44% -15.47%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 6.92% -8.24% -15.21%
Invested Capital Q/Q Growth		 0.00% 0.00% 1,047.62% 2.76% -18.90% -1.57%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 98.77% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.49% 100.38% 97.44% 95.35% 90.19% 97.11%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -44.73% -81.78% -37.54% -83.59% -68.01% -64.06%
Cash Return on Invested Capital (CROIC)		 0.00% -485.79% -275.70% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -44.73% -81.78% -37.54% -83.59% -68.01% -64.06%
Return on Equity Simple (ROE_SIMPLE)		 -44.73% -61.34% -37.63% -122.52% -45.01% 0.00%
Net Operating Profit after Tax (NOPAT)		 -23 -66 -46 -66 -73 -116
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -13.50% -25.59% -7.52% -26.37% -21.30% -21.63%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -71.22% -27.63% -31.22%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -34 -94 -58 -100 -120 -189
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -34 -91 -55 -97 -119 -191
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.55 1.88 2.11 3.97
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.65 2.54 2.30 4.22
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.18 0.09 0.12
Long-Term Debt to Equity		 0.00 0.00 0.00 0.18 0.09 0.12
Financial Leverage		 -1.06 -0.94 -0.91 -0.99 -1.06 -1.09
Leverage Ratio		 1.07 1.08 1.10 1.29 1.34 1.29
Compound Leverage Factor		 1.08 1.08 1.08 1.23 1.20 1.26
Debt to Total Capital		 0.00% 0.00% 0.00% 15.31% 8.30% 10.88%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 15.31% 8.30% 10.88%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 84.69% 91.70% 89.12%
Debt to EBITDA		 0.00 0.00 0.00 -0.15 -0.18 -0.21
Net Debt to EBITDA		 0.00 0.00 0.00 0.88 2.11 1.94
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.15 -0.18 -0.21
Debt to NOPAT		 0.00 0.00 0.00 -0.22 -0.30 -0.35
Net Debt to NOPAT		 0.00 0.00 0.00 1.30 3.46 3.19
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.22 -0.30 -0.35
Altman Z-Score		 0.00 0.00 0.77 -3.34 2.84 5.03
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 27.10 13.18 8.16 3.22 7.25 6.29
Quick Ratio		 26.63 12.83 7.94 3.09 7.05 6.17
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -88 -37 -49 -70 -88
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -245.26 0.00 -53.79 0.00 -16.08
Operating Cash Flow to Interest Expense		 -143.88 -127.64 0.00 -69.96 0.00 -24.00
Operating Cash Flow Less CapEx to Interest Expense		 -143.88 -127.64 0.00 -69.96 0.00 -24.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -4.23 18 8.78 -7.44 -10 -39
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 22 -9.35 -16 -3.00 -28
Enterprise Value (EV)		 0.00 0.00 -59 61 259 948
Market Capitalization		 0.00 0.00 83 147 510 1,319
Book Value per Share		 $0.29 $5.54 $4.02 $1.95 $3.29 $3.37
Tangible Book Value per Share		 $0.29 $4.56 $3.39 $1.44 $3.02 $3.17
Total Capital		 76 152 151 92 263 373
Total Debt		 0.00 0.00 0.00 14 22 41
Total Long-Term Debt		 0.00 0.00 0.00 14 22 41
Net Debt		 -80 -134 -142 -86 -252 -371
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.58 -6.73 -14 -28 -31 -59
Debt-free Net Working Capital (DFNWC)		 79 127 128 72 243 353
Net Working Capital (NWC)		 79 127 128 72 243 353
Net Nonoperating Expense (NNE)		 11 27 10 30 36 67
Net Nonoperating Obligations (NNO)		 -80 -134 -142 -86 -252 -371
Total Depreciation and Amortization (D&A)		 0.00 2.62 3.18 3.26 1.25 -1.82
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.45) ($1.84) ($2.44) ($1.54) ($2.06)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 28.13M 30.86M 39.16M 70.46M 89.33M
Adjusted Diluted Earnings per Share		 $0.00 ($3.45) ($1.84) ($2.44) ($1.54) ($2.06)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 28.13M 30.86M 39.16M 70.46M 89.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($3.45) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 27.38M 38.06M 41.33M 75.37M 99.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -66 -46 -66 -73 -116
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -205.93 -261.38 0.00 -109.13 0.00 -34.53
NOPAT to Interest Expense		 -140.98 -183.00 0.00 -71.42 0.00 -21.24
EBIT Less CapEx to Interest Expense		 -205.93 -261.38 0.00 -109.13 0.00 -34.53
NOPAT Less CapEx to Interest Expense		 -140.98 -183.00 0.00 -71.42 0.00 -21.24
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.16% 0.00% 0.00% 0.00% 0.00% -8.68%

Quarterly Metrics And Ratios for Definium Therapeutics

This table displays calculated financial ratios and metrics derived from Definium Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 75,368,359.00 75,553,266.00 76,087,943.00 - 99,698,129.00
DEI Adjusted Shares Outstanding		 - - - - - - 75,368,359.00 75,553,266.00 76,087,943.00 - 99,698,129.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.31 -0.57 -0.88 - -0.77
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -13.95% -359.83% -117.70% 62.75% 10.01% -53.44% 54.30% -312.87% -313.69% -39.71% -212.64%
EBIT Growth		 -13.30% -314.01% -113.12% 63.72% 13.74% -50.84% 54.73% -290.95% -314.56% -40.94% -214.98%
NOPAT Growth		 -27.28% -59.74% -6.43% 16.19% -14.69% -46.20% -44.83% -67.24% -84.21% -46.57% -84.15%
Net Income Growth		 -8.72% -386.72% -119.22% 79.90% 23.65% -45.58% 57.08% -630.17% -391.56% -45.18% -230.21%
EPS Growth		 19.64% -281.25% -75.38% 65.79% 40.00% 121.31% 69.30% -92.31% -188.89% -430.77% -102.86%
Operating Cash Flow Growth		 -78.83% -60.04% -24.51% -44.38% -3.40% -23.28% -77.24% -48.08% -71.99% -69.52% -44.91%
Free Cash Flow Firm Growth		 23.32% 277.16% 3,357.74% -221.09% -93.05% -3,030.10% -332.56% -205.11% 83.61% 74.37% 118.23%
Invested Capital Growth		 -726.35% -184.80% -4,600.86% -54.12% -14.74% -40.29% 98.34% 33.08% -333.82% -270.60% -7,607.74%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 38.30% -30.52% -129.75% 79.95% -49.06% -122.54% 31.28% -81.11% -49.36% 23.36% -50.80%
EBIT Q/Q Growth		 37.30% -29.78% -124.55% 80.14% -49.06% -126.94% 32.61% -71.49% -58.07% 22.85% -50.61%
NOPAT Q/Q Growth		 25.93% -2.72% 0.00% -10.15% -1.37% -30.94% 0.93% -27.19% -11.65% -4.18% -24.47%
Net Income Q/Q Growth		 38.47% -33.15% -127.96% 89.24% -133.75% -153.88% 32.79% -83.07% -57.37% 25.02% -52.86%
EPS Q/Q Growth		 40.79% -35.56% -86.89% 77.19% -3.85% 148.15% -369.23% -42.86% -56.00% 44.87% -65.12%
Operating Cash Flow Q/Q Growth		 -20.09% -23.68% 19.28% -20.43% 14.00% -47.47% -16.05% -0.61% 0.11% -45.35% 0.80%
Free Cash Flow Firm Q/Q Growth		 -190.80% 108.01% 3,981.28% -140.80% -44.75% -21.56% -223.93% 46.47% 92.22% -90.15% 330.35%
Invested Capital Q/Q Growth		 29.95% 2.76% -465.56% 60.00% 47.84% -18.90% 93.31% -1,513.90% -238.12% -1.57% -39.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.91% 96.34% 97.80% 53.00% 83.11% 92.98% 92.73% 98.99% 98.55% 95.78% 97.21%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -61.52% -83.59% -76.79% -66.26% -54.61% -68.01% -37.07% -59.11% -85.59% -64.06% -94.70%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -61.52% -83.59% -76.79% -66.26% -54.61% -68.01% -37.07% -59.11% -85.59% -64.06% -94.70%
Return on Equity Simple (ROE_SIMPLE)		 -79.99% 0.00% -63.92% -50.50% -37.30% 0.00% -34.84% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -15 -16 -16 -17 -17 -23 -23 -29 -32 -33 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.16% -7.31% -21.14% 6.71% 1.96% -7.12% -0.36% -6.79% -16.06% -5.50% -12.82%
Return On Investment Capital (ROIC_SIMPLE)		 - -16.85% - - - -8.63% -9.19% -12.64% -18.70% -8.93% -12.97%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -19 -25 -56 -11 -16 -37 -25 -43 -68 -53 -79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -24 -55 -11 -16 -37 -25 -46 -68 -52 -79
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.30 1.88 1.92 2.56 1.57 2.11 1.98 2.64 6.87 3.97 6.76
Price to Tangible Book Value (P/TBV)		 1.66 2.54 2.14 2.85 1.69 2.30 2.17 2.96 8.11 4.22 7.28
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.15 0.18 0.07 0.12 0.09 0.09 0.10 0.22 0.31 0.12 0.15
Long-Term Debt to Equity		 0.15 0.18 0.07 0.12 0.09 0.09 0.10 0.22 0.31 0.12 0.15
Financial Leverage		 -1.03 -0.99 -1.13 -1.09 -1.05 -1.06 -1.10 -1.07 -1.12 -1.09 -1.11
Leverage Ratio		 1.29 1.29 1.32 1.33 1.29 1.34 1.32 1.38 1.42 1.29 1.35
Compound Leverage Factor		 1.21 1.24 1.29 0.71 1.07 1.24 1.22 1.36 1.40 1.24 1.31
Debt to Total Capital		 12.78% 15.31% 6.75% 10.72% 8.49% 8.30% 9.00% 18.18% 23.62% 10.88% 12.76%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 12.78% 15.31% 6.75% 10.72% 8.49% 8.30% 9.00% 18.18% 23.62% 10.88% 12.76%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 87.22% 84.69% 93.25% 89.28% 91.51% 91.70% 91.00% 81.82% 76.38% 89.12% 87.24%
Debt to EBITDA		 -0.18 -0.15 -0.11 -0.22 -0.23 -0.18 -0.25 -0.33 -0.23 -0.21 -0.17
Net Debt to EBITDA		 1.32 0.88 1.87 2.02 2.54 2.11 2.50 1.59 0.96 1.94 1.36
Long-Term Debt to EBITDA		 -0.18 -0.15 -0.11 -0.22 -0.23 -0.18 -0.25 -0.33 -0.23 -0.21 -0.17
Debt to NOPAT		 -0.23 -0.22 -0.21 -0.38 -0.37 -0.30 -0.28 -0.45 -0.38 -0.35 -0.30
Net Debt to NOPAT		 1.73 1.30 3.57 3.46 4.13 3.46 2.80 2.16 1.59 3.19 2.46
Long-Term Debt to NOPAT		 -0.23 -0.22 -0.21 -0.38 -0.37 -0.30 -0.28 -0.45 -0.38 -0.35 -0.30
Altman Z-Score		 -0.69 -1.33 1.26 3.66 3.51 3.75 3.42 1.38 1.73 6.06 7.17
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.85 3.22 3.91 5.92 9.00 7.25 7.27 4.98 3.30 6.29 4.69
Quick Ratio		 3.78 3.09 3.87 5.81 8.88 7.05 6.97 4.82 3.20 6.17 4.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.41 0.67 27 -11 -16 -20 -64 -34 -2.66 -5.06 12
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -25.63 1.53 63.31 0.00 -22.32 -30.07 -106.14 -14.63 -2.09 -3.99 9.36
Operating Cash Flow to Interest Expense		 -50.69 -46.84 -38.24 0.00 -23.65 -38.64 -48.87 -12.66 -23.21 -33.89 -34.24
Operating Cash Flow Less CapEx to Interest Expense		 -50.69 -46.84 -38.24 0.00 -23.65 -38.64 -48.87 -12.66 -23.21 -33.89 -34.24
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -7.65 -7.44 -42 -17 -8.78 -10 -0.70 -11 -38 -39 -54
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -6.73 -16 -43 -5.91 -1.13 -3.00 41 5.57 -29 -28 -53
Enterprise Value (EV)		 21 61 139 299 140 259 217 294 728 948 1,552
Market Capitalization		 124 147 377 518 411 510 441 490 897 1,319 1,884
Book Value per Share		 $2.42 $1.95 $4.10 $2.81 $3.63 $3.29 $2.96 $2.45 $1.72 $3.37 $2.80
Tangible Book Value per Share		 $1.88 $1.44 $3.68 $2.53 $3.36 $3.02 $2.69 $2.19 $1.45 $3.17 $2.60
Total Capital		 110 92 210 226 287 263 245 227 171 373 320
Total Debt		 14 14 14 24 24 22 22 41 40 41 41
Total Long-Term Debt		 14 14 14 24 24 22 22 41 40 41 41
Net Debt		 -104 -86 -238 -219 -271 -252 -224 -197 -169 -371 -333
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -29 -28 -62 -37 -29 -31 -21 -32 -59 -59 -74
Debt-free Net Working Capital (DFNWC)		 89 72 190 206 266 243 191 151 150 353 299
Net Working Capital (NWC)		 89 72 190 206 266 243 191 151 150 353 299
Net Nonoperating Expense (NNE)		 2.79 8.32 39 -11 -3.67 12 0.84 14 35 17 36
Net Nonoperating Obligations (NNO)		 -104 -86 -238 -219 -271 -252 -224 -197 -169 -371 -333
Total Depreciation and Amortization (D&A)		 0.79 0.89 0.53 0.00 0.00 0.73 0.00 -2.42 0.14 0.46 0.59
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.61) ($1.14) ($0.08) ($0.18) ($0.14) ($0.27) ($0.50) ($0.78) ($0.51) ($0.71)
Adjusted Weighted Average Basic Shares Outstanding		 39.72M 39.16M 47.86M 71.91M 77.91M 70.46M 85.07M 85.35M 85.89M 89.33M 108.79M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.61) ($1.14) ($0.26) ($0.27) $0.13 ($0.35) ($0.50) ($0.78) ($0.43) ($0.71)
Adjusted Weighted Average Diluted Shares Outstanding		 39.72M 39.16M 47.86M 75.30M 80.24M 70.46M 87.09M 85.35M 85.89M 89.33M 108.79M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.61) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 40.09M 41.33M 71.87M 72.14M 73.33M 75.37M 75.55M 76.09M 98.51M 99.70M 109.07M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -16 -16 -17 -17 -23 -23 -29 -32 -33 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -58.19 -56.42 -128.16 0.00 -22.65 -56.96 -41.83 -18.47 -53.57 -41.53 -63.70
NOPAT to Interest Expense		 -46.13 -35.41 -35.81 0.00 -23.87 -34.64 -37.39 -12.25 -25.09 -26.27 -33.30
EBIT Less CapEx to Interest Expense		 -58.19 -56.42 -128.16 0.00 -22.65 -56.96 -41.83 -18.47 -53.57 -41.53 -63.70
NOPAT Less CapEx to Interest Expense		 -46.13 -35.41 -35.81 0.00 -23.87 -34.64 -37.39 -12.25 -25.09 -26.27 -33.30
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.68% -6.71%

Financials Breakdown Chart

Key Financial Trends

Definium Therapeutics (NASDAQ:DFTX) posted another quarter of heavy losses in Q1 2026, but it remains well-capitalized with a large cash and investment balance. The company reported no revenue, continued to spend aggressively on research and development, and burned cash from operations. At the same time, its balance sheet still shows substantial liquidity, which should give it time to continue funding development.

  • Cash and equivalents were $262.5 million, and short-term investments were $110.9 million, giving the company a strong near-term liquidity position.
  • Total current assets stood at $380.6 million, far above current liabilities of $81.1 million.
  • The company generated $42.0 million from investing activities, mainly from sales and/or maturities of investments, helping offset operating losses.
  • Net cash increased by $4.7 million in Q1 2026 despite a large operating loss, reflecting strong investment liquidity and modest financing inflows.
  • There was no reported revenue in Q1 2026, so the business still appears to be in a pre-commercial stage.
  • Goodwill of $19.9 million remains on the balance sheet, but there was no indication of a new impairment charge in the data provided.
  • Long-term debt was $40.8 million, which is manageable relative to total equity of $278.8 million, but it still adds fixed obligations.
  • The company reported a net loss of $77.1 million for Q1 2026, wider than the $50.4 million loss in Q4 2025.
  • Operating cash flow was negative $42.6 million, showing the core business is still consuming significant cash.
  • Research and development expense rose to $41.5 million and SG&A increased to $17.7 million, driving total operating expenses up to $59.2 million.

Quarter-over-quarter, expenses climbed faster than the company’s financial results improved. Operating expenses increased from $47.6 million in Q4 2025 to $59.2 million in Q1 2026, while the net loss deepened from $50.4 million to $77.1 million. That suggests the company is still in an investment-heavy phase, with no evidence yet of operating leverage.

On a longer-term basis, the balance sheet has improved materially from a year ago. Total assets were $401.3 million in Q1 2026, versus $275.3 million in Q1 2025, while equity rose to $278.8 million from $222.8 million. However, that progress came alongside significant share issuance over time, which likely diluted existing shareholders.

Bottom line: Definium Therapeutics has enough cash to keep funding operations for now, but the business is still far from profitability. Investors will likely focus on whether future clinical progress can eventually translate into revenue or a reduction in burn rate.

07/19/26 05:41 AM ETAI Generated. May Contain Errors.

Definium Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Definium Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Definium Therapeutics' net income appears to be on an upward trend, with a most recent value of -$183.79 million in 2025, rising from -$33.94 million in 2020. The previous period was -$108.68 million in 2024. View Definium Therapeutics' forecast to see where analysts expect Definium Therapeutics to go next.

Definium Therapeutics' total operating income in 2025 was -$166.31 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $166.31 million

Over the last 5 years, Definium Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Definium Therapeutics' total liabilities were at $107.77 million at the end of 2025, a 77.5% increase from 2024, and a 1,807.1% increase since 2020.

In the past 5 years, Definium Therapeutics' cash and equivalents has ranged from $80.09 million in 2020 to $273.74 million in 2024, and is currently $257.84 million as of their latest financial filing in 2025.

Over the last 5 years, Definium Therapeutics' book value per share changed from 0.29 in 2020 to 3.37 in 2025, a change of 1,083.7%.


Related Companies

Financial statements for NASDAQ:DFTX last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel